FIGURE LEGENDS
Figure 1. Plasma concentration-time profile of mycophenolic acid.
Figure 2. Comparison of Ka and its variability between base model (A) and covariate model (B). The random variable η is normally distributed with mean zero and variance of ω², which is the deviation of ηi from population value.
Figure 3. The variation of clearance rate before (A, B) and after addition of covariate (C, D). The random variable η is normally distributed with mean zero and variance of ω², which is the deviation of ηi from population value.
Figure 4. Covariate effects on pharmacokinetic parameters of mycophenolic acid. The X-axis is inter-individual variation (η) expressed by the mean±SD.
Figure 5. Distribution of estimated glomerular filtration rate (eGFR) calculated with the measurement of serum creatinine and cystatin C.
Figure 6. Goodness-of-fit plots of mycophenolic acid for population pharmacokinetic model. Observed concentration versus population (A) and individual (B) predictions, and conditional weighted residuals versus population predictions (C) and time from dose (D). y =±2 represents 95% confidence interval.
Figure 7. Visual predictive check for mycophenolic acid. The blank dots are actual observations. The redlines are 5th (solid line), 50th and 95th (dash lines) quantiles from actual observations within their simulated 95% CIs (shaded areas).
SUPPORTING INFORMATION
Supplemental Figure1.The effect of prednisolone on absorption (P=0.017).
Supplemental Table 1. Dosage simulations of mycophenolate mofetil for ANCA-associated nephritis children (N=1000) based on different estimated glomerular filtration rates (eGFR) and myeloperoxidase